Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960353 | 0.89 | KDM4E (0.38) | KDM4ESMN1; SMN2KDM5BKCNH2CYP19A1 | |
| SCHEMBL2343622 | 0.85 | KCNH2 (0.40) | KDM4ESMN1; SMN2KDM5BKCNH2CYP19A1 | |
| SCHEMBL16628721 | 0.83 | KCNH2 (0.42) | KDM4ESMN1; SMN2KDM5BKCNH2CYP19A1 | |
| SCHEMBL1961789 | 0.80 | KDM5B (0.38) | KDM4ESMN1; SMN2KDM5BKCNH2CYP19A1 | |
| SCHEMBL13463409 | 0.77 | KCNH2 (0.40) | KDM4EKDM5BKCNH2KLKB1 | |
| SCHEMBL2345517 | 0.76 | CYP11B1 (0.38) | KCNH2CYP19A1 | |
| SCHEMBL13463859 | 0.74 | KCNH2 (0.47) | KDM5BKCNH2HDAC1KDM4AKDM5A | |
| SCHEMBL1959935 | 0.73 | KCNH2 (0.39) | KDM5BKCNH2CYP19A1 | |
| SCHEMBL1963287 | 0.71 | RAB9A (0.42) | KDM4EKDM5BKCNH2CYP19A1HDAC1 | |
| SCHEMBL13463582 | 0.70 | KCNH2 (0.41) | KDM5BKCNH2KDM4AKDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779141-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1521754-B1 | VIRAL INHIBITORS | LEUVEN K U RES & DEV (BE) | 2011-08-31 | — | — | EP | disclosed |
| EP-2332938-A1 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-06-15 | — | — | EP | disclosed |
| US-7737162-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100004281-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20050239821-A1 | Viral inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521754-A2 | VIRAL INHIBITORS | K.U.Leuven Research & Development (BE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005286-A2 | VIRAL INHIBITORS | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004281-A1 | VIRAL INHIBITORS | ZC3HAV1, MAVS, HAVCR2 | KDM4E 519/4885SMN1; SMN2 3179/4885KDM5B 590/4885 |
| US-20050239821-A1 | Viral inhibitors | ZC3HAV1, ZC3HAV1L, ACE | KDM4E 782/4885SMN1; SMN2 3260/4885KDM5B 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.